156 related articles for article (PubMed ID: 12559898)
1. Enzyme replacement in Anderson-Fabry disease.
Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
[No Abstract] [Full Text] [Related]
2. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
Basic-Jukic N; Kes P; Mokos I; Coric M
Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
[No Abstract] [Full Text] [Related]
3. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
Warnock DG
J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
[No Abstract] [Full Text] [Related]
4. Enzyme replacement in Fabry disease: the essence is in the kidney.
Schiffmann R
Ann Intern Med; 2007 Jan; 146(2):142-4. PubMed ID: 17179053
[No Abstract] [Full Text] [Related]
5. Agalsidase beta (Fabrazyme) for Fabry disease.
Med Lett Drugs Ther; 2003 Sep; 45(1165):74-5. PubMed ID: 12968124
[No Abstract] [Full Text] [Related]
6. First treatment for Fabry's disease.
FDA Consum; 2003; 37(4):4. PubMed ID: 12971327
[No Abstract] [Full Text] [Related]
7. Agalsidase: a second look. With hindsight: full data challenge efficacy.
Prescrire Int; 2003 Oct; 12(67):168-71. PubMed ID: 14619828
[No Abstract] [Full Text] [Related]
8. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
Wanner C
Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
[No Abstract] [Full Text] [Related]
9. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
[No Abstract] [Full Text] [Related]
10. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
Banikazemi M; Desnick RJ
Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
[No Abstract] [Full Text] [Related]
11. PR interval and the response to enzyme-replacement therapy for Fabry's disease.
Waldek S
N Engl J Med; 2003 Mar; 348(12):1186-7. PubMed ID: 12646684
[No Abstract] [Full Text] [Related]
12. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
Hollak CE; Linthorst GE
Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
[No Abstract] [Full Text] [Related]
13. Enzyme replacement therapy of Fabry disease.
Clarke JT; Iwanochko RM
Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
[TBL] [Abstract][Full Text] [Related]
14. Anderson-Fabry disease: enzyme replacement therapy.
Leon-Mateos A; Fernández-Redondo V; Beiras A; Toribio J
Acta Derm Venereol; 2004; 84(1):88-9. PubMed ID: 15040494
[No Abstract] [Full Text] [Related]
15. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
del Toro N; Milán JA; Palma A
Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
[No Abstract] [Full Text] [Related]
16. Shire drops 'emergency' Fabry's disease drug.
Fox JL
Nat Biotechnol; 2012 Jun; 30(6):478. PubMed ID: 22678371
[No Abstract] [Full Text] [Related]
17. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy.
Germain DP
Clin Ther; 2007; 29 Suppl A():S17-8. PubMed ID: 17580237
[No Abstract] [Full Text] [Related]
18. Agalsidase treatment for Fabry disease: uses and rivalries.
Schiffmann R
Genet Med; 2010 Nov; 12(11):684-5. PubMed ID: 20975568
[No Abstract] [Full Text] [Related]
19. Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.
Beck M
Expert Opin Investig Drugs; 2002 Jun; 11(6):851-8. PubMed ID: 12036428
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
Martin-Suárez I; Suárez-Marrero C
Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
[No Abstract] [Full Text] [Related]
[Next] [New Search]